LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has completed the molecule design phase of its malaria NCE (new chemical entity) project, and has issued requests for quotes to synthesize up to twelve compounds for testing.
